Advertisement

Zydus Cadila to begin phase II Covid-19 vaccine clinical trials from Aug 6

Follow The Hawk on Google News+ Follow

Advertisement


New Delhi: "The company reports that the doses of the vaccine administered to healthy volunteers in the phase I clinical trial, which began on July 15, 2020, has been well tolerated,"Cadila Healthcare, the listed entity of the group, said in a regulatory filing.

Zydus Cadila Chairman Pankaj R Patel said the phase I dosing to establish the safety of ZyCoV-D is an important milestone.

Advertisement

"All the subjects in phase I clinical trial were closely monitored in a clinical pharmacological unit for 24 hours post dosing for safety and for 7 days thereafter and the vaccine was found to be very safe. We now begin the phase II clinical trials and look forward to evaluating the safety and immunogenicity of the vaccine in a larger population, he added.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

Last month, Zydus had received approval from domestic authorities to start human trials for its Covid-19 vaccine contender - the second Indian pharmaceutical firm to get such nod amid a surge in novel coronavirus infections worldwide.

It got approval a few days after India's first indigenous Covid-19 vaccine candidate COVAXIN, developed by city-based Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology, got the nod for human clinical trials from the Drug Controller General of India

Advertisement

Shares of Cadila Healthcare were trading at Rs 407.20 apiece on BSE, up 1.08 per cent from its previous

—PTI

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST